Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

Journal of Clinical Investigation

Volumn 111, Issue 5, 2003, Pages 737-747

  Matsusue, Kimihiko ^a   Haluzik, Martin ^b,d   Lambert, Gilles ^c,e   Yim, Sun Hee ^a   Gavrilova, Oksana ^b   Ward, Jerrold M ^a   Brewer Jr , Bryan ^c   Reitman, Marc L ^b,f   Gonzalez, Frank J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d CHARLES UNIVERSITY   (Czech Republic)

^e INSERM   (France)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; CRE RECOMBINASE; FATTY ACID; FATTY ACID SYNTHASE; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; EXON; FATTY ACID BLOOD LEVEL; FATTY LIVER; GENE DELETION; GENE DISRUPTION; GENE LOSS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; HYPERGLYCEMIA; INSULIN RESISTANCE; LEPTIN; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, INBRED C57BL; MICE, OBESE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LDL; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0037373008     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317223     Document Type: Article

References (55)

1. Hihi, A.K., Michalik, L., and Wahli, W. 2002. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell. Mol. Life Sci. 59:790-798.
2. Bocher, V., Pineda-Torra, I., Fruchart, J.C., and Staels, B. 2002. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci. 967:7-18.
3. Rosen, E.D., et al. 2002. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 16:22-26.
4. Akiyama, T.E., et al. 2002. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22:2607-2619.
5. Chawla, A., et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7:161-171.
6. Barak, Y., et al. 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
7. Kubota, N., et al. 1999. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609.
8. Rosen, E.D., et al. 1999. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4:611-617.
9. Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. 1994. Peroxisome proliferator-acrivated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 135:798-800.
10. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M. 1994. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1224-1234.
11. Lefebvre, A.M., et al. 1998. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4:1053-1057.
12. Saez, E., et al. 1998. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4:1058-1061.
13. Seed, B. 1998. PPARgamma and colorectal carcinoma: conflicts in a nuclear family. Nat. Med. 4:1004-1005.
14. Moore, K.J., Fitzgerald, M.L., and Freeman, M.W. 2001. Peroxisome proliferator-activated receptors in macrophage biology: friend or foe? Curr. Opin. Lipidol. 12:519-527.
15. Fajas, L., et al. 1997. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 272:18779-18789.
16. Peters, J.M., Rusyn, I., Rose, M.L., Gonzalez, F.J., and Thurman, R.G. 2000. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis. 21:823-826.
17. Burant, C.F., et al. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:2900-2908.
18. Chao, L., et al. 2000. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106:1221-1228.
19. Memon, R.A., et al. 2000. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 141:4021-4031.
20. Rahimian, R., et al. 2001. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of noninsulin dependent diabetes mellitus. Mol. Cell. Biochem. 224:29-37.
21. Bedoucha, M., Atzpodien, E., and Boelsterli, U.A. 2001. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol. 35:17-23.
22. Yakar, S., et al. 1999. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 96:7324-7329.
23. Hayhurst, G.P., Lee, Y.H., Lambert, G., Ward, J.M., and Gonzalez, F.J. 2001. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell. Biol. 21:1393-1403.
24. Bligh, E.G., and Dyer, W.J. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:911-917.
25. Iverius, P.H., and Brunzell, J.D. 1985. Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. Am. J. Physiol. 249:E107-E114.
26. Vaisman, B.L., et al. 2001. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. 108:303-309. doi:10.1172/JCI200112517.
27. Haluzik, M., et al. 2002. Adrenalectomy improves diabetes in A-ZIP/F-1 lipoatrophic mice by increasing both liver and muscle insulin sensitivity. Diabetes. 51:2113-2118.
28. Peters, J.M., Rusyn, I., Rose, M.L., Gonzalez, F.J., and Thurman, R.G. 2000. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis. 21:823-826.
29. Postic, C., et al. 1999. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knockouts using Cre recombinase. J. Biol. Chem. 274:305-315.
30. Davies, G.F., McFie, P.J., Khandelwal, R.L., and Roesler, W.J. 2002. Unique ability of troglitazone to up-regulate peroxisome proliferatoractivated receptor-gamma expression in hepatocytes. J. Pharmacol. Exp. Ther. 300:72-77.
31. Liang, C.P., and Tall, A.R. 2001. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J. Biol. Chem. 276:49066-49076.
32. Drochmans, P., Wanson, J.C., and Mosselmans, R. 1975. Isolation and subfractionation on ficoll gradients of adult rat hepatocytes. Size, morphology, and biochemical characteristics of cell fractions. J. Cell Biol. 66:1-22.
33. Kishida, K., et al. 2001. Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 276:48572-48579.
34. Shimomura, I., Bashmakov, Y., and Horton, J.D. 1999. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274:30028-30032.
35. Zinman, B. 2001. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes. Metab. 3(Suppl. 1):S34-S43.
36. Lehmann, J.M., et al. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:12953-12956.
37. Horton, J.D., Goldstein, J.L., and Brown, M.S. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:1125-1131. doi:10.1172/JCI200215593.
38. Yahagi, N., et al. 2002. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J. Biol. Chem. 277:19353-19357.
39. Castelein, H., et al. 1994. The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J. Biol. Chem. 269:26754-26758.
40. Miller, C.W., and Ntambi, J.M. 1996. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proc. Natl. Acad. Sci. U. S. A. 93:9443-9448.
41. DeLuca, J.G., et al. 2000. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. Mol. Pharmacol. 58:470-476.
42. Yoshikawa, T., et al. 2001. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell Biol. 21:2991-3000.
43. Repa, J.J., et al. 2000. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14:2819-2830.
44. Jansen, H., Verhoeven, A.J., and Sijbrands, E.J. 2002. Hepatic lipase: a proor anti-atherogenic protein? J. Lipid Res. 43:1352-1362.
45. Streicher, R., et al. 1996. SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. J. Biol. Chem. 271:7128-7133.
46. Shimano, H., et al. 1997. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J. Clin. Invest. 100:2115-2124.
47. Lebovitz, H.E., and Banerji, M.A. 2001. Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Horm. Res. 56:265-294.
48. Picard, F., and Auwerx, J. 2002. PPAR(gamma) and glucose homeostasis. Annu. Rev. Nutr. 22:167-197.
49. Dresner, A., et al. 1999. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103:253-259.
50. Roden, M., et al. 1996. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 97:2859-2865.
51. McGarry, J.D., and Dobbins, R.L. 1999. Fatty acids, lipotoxicity and insulin secretion. Diabetologia. 42:128-138.
52. Sako, Y., and Grill, V.E. 1990. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology. 127:1580-1589.
53. Hajri, T., Han, X.X., Bonen, A., and Abumrad, N.A. 2002. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J. Clin. Invest. 109:1381-1389. doi:10.1172/JCI200214596.
54. Rieusset, J., et al. 1999. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes. 48:699-705.
55. Yu, S., et al. 2003. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 278:498-505.